Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-TARDB-002 in TARDBP-mutated ALS
NCT07703462Phase 2Enrolling by invitation
- Sponsor
- n-Lorem Foundation
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of nL-TARDB-002 in amyotrophic lateral sclerosis (ALS), sponsored by n-Lorem Foundation. Planned start Dec 2026; status: enrolling by invitation.
02
Drugs
nL-TARDB-002
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07703462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07703462.